Skip to content

About Us

Recombinetics is a recognized leader in gene editing to advance human and farm animal health and welfare.

Founded in 2008, Recombinetics is a privately held biotechnology company that aims at helping to solve some of the world’s most intractable challenges through gene editing. Recombinetics is delivering viable products and generating revenues today from the large and growing biomedical and agricultural markets.

Recombinetics focused its early-stage development on the application of precision genetic technologies and active patent filings in animals. Development of advanced “gene-editing” technologies for commercial purposes began in 2011. Today, Recombinetics is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.

Recombinetics’ first gene-edited animals are generating revenues today with a pipeline of animals under development for the large biomedical and agricultural markets.

Company Firsts

Recombinetics is a company built on firsts.

With a robust intellectual property portfolio, RCI leverages its research platform to commercialize and deploy its invented and licensed technologies across key markets.

RCI’s growing global patent portfolio includes 33 issued patents, more than 170 additional applications filed, and first use and enabling patents for livestock for both CRISPR and TALENs.

Here are some of RCI’s achievements in science:

2018

  • First gene edited thermotolerant cattle born
 

2017

  • First gene edited chickens produced in Europe
  • First gene-edited hornless born
  • First patent issued in China for gene editing large animals
  • First patent issued in Europe for gene editing large animals
 

2008-2016

  • First pig model of congenital heart failure developed
  • First pig model of polycystic kidney diseases developed
  • First-of-its-kind pig model of Neurofibromatosis Type 1 developed
  • First utility patent filed in the US for methods for producing transgenic pigs
  • First to make APOBEC pigs for PERV-safe organs
  • First DNA transposon engineered pig born
  • First gene-edited hornless cattle born
  • First to gene-edit for accelerated reproduction OPU in cattle
  • First patent issued in the US for CRISPR gene editing in animals optimized to prevent re-cutting of the target sequence
  • First to achieve multi-gene editing in pigs and cattle
  • First to enable CRISPR in large animals
  • First filed CRISPR utility patents in large animals
  • First to transfer native allele in species
  • First TALENS use to knockout & break genes in embryos

Firsts in Agriculture

Firsts in Recombinetics Core Gene Editing Platform

Firsts in Biomedicine

Business Highlights

Recombinetics collaborates with public and private leaders to deliver gene editing solutions.

Some key business highlights include:

2018

  • Collaboration with Mayo Clinic announced to develop cardiomyocytes
  • Alliance to end castration of swine announced with collaborators in the United States and the Netherlands
  • Alliance to end dehorning of cattle announced with collaborators in Canada; first commercial deal for polled genetics
  • Brazil authorities concluded gene-edited dehorned cattle aren’t GMOs
  • Target TB announced with collaborators in Ireland and Northern Ireland to curb tuberculosis in cattle
 

2017

  • Collaboration with Mayo Clinic announced to pig model of congenital heart failure
  • Collaboration with Children’s Minnesota announced to develop pig model of phenylketonuria
  • Announcement of major developments in neurofibromatosis Type 1 model funded by Children’s Tumor Foundation

Firsts in Agriculture

Firsts in Recombinetics Core Gene Editing Platform

Firsts in Biomedicine

Publications

Our Science is Peer-Reviewed. 

Our scientific findings are often published in peer-reviewed scientific journals and often cited by other scientists in their published research. Our work has been documented in over 300 peer-reviewed publications and written been covered many times by both scientific and consumer media outlets.

female researcher carrying out research experiments in a chemistry lab (color toned image)

Here are some of our recent publications:

About Cancer

Engineered swine models of cancer
Published in the Frontiers in Genetics

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
Published in Nature’s Communication Biology

A new tool for mapping breast cancer risk in the tumor microenvironment
Published in Cancer Research

About Cardiovascular Disease

Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model
Published in Translational Research  

About Orphan Disease

TALEN-based gene correction for epidermolysis bullosa
Published in Molecular Therapy

About Gene Editing and Advanced Reproduction of Pigs

In vivo genome editing using a high-efficiency TALEN system
Published in Nature

Precision editing of large animal genomes
Published in Advances in Genetics

Efficient TALEN-mediated gene knockout in livestock
Published in Proceedings of the National Academy of Sciences

Precise genome editing of PDX1 by direct injection of transcription activator-like effector nucleases (TALENS) into Parthenogenetic Pig Embryos
Published in Reproduction, Fertility and Development

Efficient Nonmeiotic Allele Introgression in Livestock Using Custom Endonucleases
Published in Proceedings of National of the National Academy of Sciences

Editing Livestock Genomes with Site-Specific Nucleases
Published in the Journal of Reproduction, Fertility and Development

Live pigs produced from genome edited zygotes
Published in Scientific Reports

TALEN-mediated gene targeting in porcine spermatogonia
Published in Molecular Reproduction and Development

Simple and efficient methods for enrichment and isolation of endonuclease modified cells
Published in PLOS One

Recombinetics develops and utilizes the best of gene editing technology to improve and lengthen human lives and to improve and grow agriculture to help feed the world’s growing population and reduce animal suffering.

Learn more about the vision and potential of Recombinetics: